|
19.11.2024 14:33:30
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | David Moore | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President, head of Corporate Development | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | ADRs | |||
| Identification code | NVO | ||||
| b) | Nature of the transaction | Purchase of ADRs | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 709.25 | 2,500 ADRs | ||||
| d) | Aggregated information
| 2,500 ADRs DKK 1,773,118.70 | |||
| e) | Date of the transaction | 2024-11-18 | |||
| f) | Place of the transaction | New York Stock Exchange | |||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | David Heiberg Landsted
+45 3077 6915 dhel@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com | Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Company Announcement No 90 / 2024
Attachment
Nachrichten zu Novo Nordisk
|
02.01.25 |
Gewinne in Europa: Am Nachmittag Gewinne im STOXX 50 (finanzen.ch) | |
|
02.01.25 |
Minuszeichen in Europa: So steht der STOXX 50 am Donnerstagmittag (finanzen.ch) | |
|
02.01.25 |
Donnerstagshandel in Europa: STOXX 50 zum Handelsstart auf grünem Terrain (finanzen.ch) | |
|
31.12.24 |
Dezember 2024: Die Expertenmeinungen zur Novo Nordisk-Aktie (finanzen.net) | |
|
31.12.24 |
STOXX 50 aktuell: STOXX 50 präsentiert sich zum Handelsende fester (finanzen.ch) | |
|
31.12.24 |
Börse Europa: STOXX 50 mit positivem Vorzeichen (finanzen.ch) | |
|
31.12.24 |
Börse Europa: So performt der STOXX 50 aktuell (finanzen.ch) | |
|
31.12.24 |
Börse Europa: STOXX 50 eröffnet wenig verändert (finanzen.ch) |
Analysen zu Novo Nordisk
| 23.12.24 | Novo Nordisk Overweight | Barclays Capital | |
| 23.12.24 | Novo Nordisk Halten | DZ BANK | |
| 20.12.24 | Novo Nordisk Underperform | Bernstein Research | |
| 20.12.24 | Novo Nordisk Neutral | UBS AG | |
| 20.12.24 | Novo Nordisk Underperform | Jefferies & Company Inc. |
Robert Halver: Ausblick 2025 | BX TV
Im zweiten Teil des grossen Jahresinterviews werfen wir mit Robert Halver, Leiter der Kapitalmarktanalyse bei der Baader Bank AG einen Ausblick auf das Jahr 2025.
Wird das Zinsthema im Jahr 2025 relevant sein? Wie entwickelt sich die Geopolitischen Konflikte und wie werden Rohstoffe und Krypto weiterlaufen? Diese und weitere Fragen beantwortet Robert Halver im heutigen Jahresausblick mit David Kunz, COO der BX Swiss AG.
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Novo Nordisk | 76.88 | 0.00% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
SMI startet freundlich -- DAX startet stabil -- Asiens Börsen uneinsDer heimische sowie der deutsche Aktienmarkt starten auf grünem Terrain. Asiens Börsen bewegen sich in unterschiedliche Richtungen.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |